To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Postherpetic Neuralgia

  • days left to enroll
  • participants needed
  • sponsor
    Haisco Pharmaceutical Group Co., Ltd.
Updated on 10 December 2021


Investigate the Efficacy and Safety of HSK16149 capsules in Chinese Postherpetic Neuralgia Following 12 Weeks Treatment in Comparison to Placebo

Condition Postherpetic neuralgia, Postherpetic Neuralgia, post-herpetic neuralgia
Treatment Placebo BID, HSK16149 20mg BID, HSK16149 40mg BID
Clinical Study IdentifierNCT05140863
SponsorHaisco Pharmaceutical Group Co., Ltd.
Last Modified on10 December 2021


Yes No Not Sure

Inclusion Criteria

Signed informed consent
Males or females aged 18-75 years of age inclusive
Outpatient, Patients can not stay in the hospital overnight
Patients must have pain present for more than 1 months after the healing of the herpes zoster skin rash
At Screening, pain scale (VAS) of 40 mm

Exclusion Criteria

Peripheral neuropathy or pain unrelated to PHN that may confuse the assessment of PHN
Skin conditions in the area affected by neurupathy that could alter sensation
Chronic systemic diseases that may affect subjects' participation in the study
Severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:1)Neutrophils < 1.5 109/L, or platelet < 90 109/L, or hemoglobin < 100 g/L, or 2)AST/ALT > 2.5 upper limit of normal (ULN), or TBIL > 1.5 ULN, or 3)Estimation of glomerular filtration rate (eGFR) < 60 mL/min / 1.73 m2, or 4)Creatine kinase > 2.0 ULN
Uncontrolled diabetes(HbA1c11.0% at screening)
History of substance abuse or alcohol abuse
Any active infections at screening
HBsAg or HCV Ab positive, or HIV Ab positive, or serum TP Ab positive
Inability or unwillingness to discontinue any other prohibited concomitant medications (see Section 6.3)
Patients who have undergone neurolytic or neurosurgical therapy 1 week before screening for postherpetic neuralgia
Failure to response to previous treatment with pregabalin at doses 300 mg/d or gabapentin at doses 1200 mg/d for treatment of PHN
History of allergic or medically significant adverse reaction to investigational products or their excipients, acetaminophen or related compounds
History of suicidal behavior or attempted suicide
Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period
Mechanical operators who are engaged in high-altitude operations, motor vehicle driving and other dangerous machinery operators
Participated in another clinical study within 30 days prior to screening
Other conditions unlikely to participate in this trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note